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Abstract
Purpose: We conducted a randomized controlled trial of 39 breast cancer survivors who were
currently taking aromatase inhibitors and experiencing painful side effects. The purpose of this
study was to investigate the role of a 6-month exercise intervention on (1) endocrine-related
quality of life and (2) overall quality of life. Methods: Eligible women completed selfadministered questionnaires at baseline and 6 months including the FACT-B +ES to assess
quality of life. The participants were randomized to either an exercise intervention group that
met twice weekly with a personal trainer or usual care. T-tests and χ2 analyses were used to
assess differences in endocrine-related quality of life over the 6-month intervention period as
well as overall quality of life. The subscales of the FACT-B were examined independently using
t-tests. Results: The average baseline endocrine-related QOL score was 56.2 for all participants
in the study. The average score did not differ by treatment group (p=0.81). Mean 6-month
changes from baseline for exercisers for the full QOL endocrine subscale was +3.3 compared to
usual care (+1.8). The difference between the two groups was not statistically significant
(p=0.32). A significant difference between the exercisers and usual care group for favorable
changes in joint pain was observed (p-value = 0.014). A moderately significant effect was also
seen for favorable changes on bloating in exercisers as compared to the usual care group (p-value
= 0.055). Conclusion: In this study, aerobic exercise, such as treadmill walking, and strength
training were associated with increases in endocrine-related quality of life. In particular, the
intervention was associated with significant decreases in joint pain. These results are
encouraging for post-menopausal women who are recommended to take AIs to improve their
prognosis.
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Introduction
Breast cancer is the leading cancer diagnosis in women in the United States. Of those
diagnosed, approximately 70% present with estrogen receptor positive tumors[1]. Aromatase
inhibitors (AIs) have been shown to be the most effective hormonal/endocrine therapy treatment
in estrogen receptor-positive breast cancer, and are therefore considered standard of care and
generally prescribed for postmenopausal women diagnosed with estrogen-receptor positive
breast cancer[1]. Because of their physiological action mechanism, AIs cause lowered levels of
estrogen which are associated with menopausal symptoms, such as hot flashes and night sweats,
which in turn may impair quality of life[2]. Given the effectiveness of AIs in reducing both risk
of recurrence and breast cancer death, and therefore the strong recommendation by clinicians for
their patients to take AIs, understanding how to reduce the severity of AI related side effects is
necessary.
Numerous studies have examined the relationship between physical activity and wellbeing, depression, anxiety, physical and emotional functioning, overall quality of life, and other
psychosocial factors in breast cancer survivors[3-4]. Exercise has been shown to improve overall
quality of life in women diagnosed with breast cancer[5-7]. However, there have not been any
studies to date that have explored the impact of exercise on side effects of AIs and on endocrinerelated QOL in women taking an AI for early stage breast cancer. QOL in cancer survivors is
commonly measured via the Functional Assessment of Cancer Therapy (FACT) questionnaire,
with subscales developed for particular cancers, e.g., FACT-Breast (FACT-B) for breast cancer.
Furthermore, an endocrine-subscale was recently developed and validated for use with the
FACT-B, the FACT-B endocrine subscale or FACT-B-ES, and is comprised of 18 questions[3].
6

An additional question was added to assess joint pain[8], as this is a common side effect of AIs,
making a 19 question endocrine subscale (Table 1). This scale has high validity and reliability
making it appropriate for measuring endocrine symptoms in women diagnosed with breast
cancer taking AIs[3].
The purpose of this study, entitled the Hormones and Physical Exercise (HOPE) Study,
was to examine, in 180 postmenopausal breast cancer survivors who have been taking an AI for
at least 6 months and reporting at least mild arthralgias (i.e., joint pain), the effect of a
randomized controlled exercise intervention vs. usual care on endocrine-related QOL. We
hypothesized that the exercise group would show improved endocrine-related QOL measures as
compared to the usual care group. This is a preliminary analysis on the first 39 women who
completed 6 months of the intervention.

Materials and Methods
Study Population
Women diagnosed with Stage I-IIIC breast cancer were eligible for the study (see Table
2). AIs are not approved for ductal carcinoma in situ (DCIS), therefore women diagnosed with
DCIS were not eligible. Participants must also have been taking an AI for at least 6 months and
be currently experiencing side effects of the medication (i.e., at least mild arthralgia, defined as >
3 on the Brief Pain Inventory (BPI) Short Form Questionnaire[9]).
To observe a maximal effect from the exercise intervention, only women reporting less
than 90 min/wk of moderate-to-vigorous intensity aerobic exercise and no strength training in the
7

previous year, as well as low fitness level (< 25 ml/kg/min, as measured by VO2 max), were
eligible to participate. Because a majority of the US population including breast cancer survivors
are physically inactive, we anticipated excluding < 25% of the population based on this
criteria[10].
Recruitment
We used the Rapid Case Ascertainment (RCA) Shared Resource Service of the Yale
Cancer Center to obtain names of women diagnosed with hormone receptor positive breast
cancer and treated at one of four hospitals in CT: Smilow Cancer Hospital at Yale-New Haven,
St. Raphael’s Hospital, Bridgeport Hospital, and Greenwich Hospital. The RCA provides the PI
with potential participants’ names and their physician’s names. Physicians were contacted first
for permission to contact the participant. If approved by the physician, we then mailed an
invitation letter to the participant, describing the study and telling her that the study manager
would call her within a week to tell her about the study and to solicit her interest and eligibility
(i.e., screening telephone call). If the participant was eligible and interested, she was scheduled
for a baseline visit.
Between April 1, 2010 and October 1, 2011, we completed 555 screening telephone calls.
Of the 555 women screened, 25% were ineligible because of discontinuation of AI treatment
because of side effects or choosing not to take AIs primarily because of potential side effects,
another 38% were ineligible for various reasons, and 25% were not interested. The remaining
12% (n = 65) were enrolled in the study and subsequently randomized to the intervention or
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usual care group. Of these 65 women, 39 completed six months of the study as of March 1, 2012,
and are included in the analyses.
Data Collection
Data collection for this study involved a screening phone call, clinic visits at baseline and
6-months, and 6 months of the exercise intervention or usual care. Participants completed a QOL
questionnaire, a 7-day daily activity log, a physical activity questionnaire, and attended a clinic
visit for physical measurements at baseline and 6 months.
Randomization
Participants were randomized to either the exercise group or usual care with equal
probability, with blocking on whether taking a bisphosphonate (Y/N) and whether pain started
after initiating the AI (Y/N). Those women randomized to the exercise group were scheduled for
their first supervised exercise training session at a local health club immediately. Women
randomized to the usual care group were contacted by a trained health professional on a monthly
basis to discuss relevant health topics so as to maintain study compliance.
Measures
Demographics and medical history. Self-administered questionnaires were completed by the
participants for the baseline visit to collect this information.
Endocrine-related QOL. QOL was measured by self-report at baseline and 6 month clinic visits
and reviewed by research staff. QOL was measured using the Functional Assessment of Cancer
9

Therapy-Breast (FACT-B) questionnaire (version 3), together with the endocrine symptom
subscale (ES) questionnaire (FACT-B+ES)[11]. The FACT-B is a 36-item questionnaire with six
subscales assessing physical, social, emotional, and functional well-being, and additional
concerns more specific to women with breast cancer (Appendix 1). The ES was designed for use
with the FACT-B and comprises 19 items (e.g., hot flashes, night sweats, weight gain, joint pain
(see Table 1)). Participants indicated how true a statement had been for them over the past 7 days
using a 5-point scale ranging from 0 (none at all) to 4 (very much). All items received equal
weighting for the analysis.
Physical activity. At baseline and 6-months, participants completed a 7-day physical activity log
(PAL)[12] and an interviewer-administered physical activity questionnaire[13] to assess physical
activity over the past 6 months. For the PAL, women recorded the type and duration of any
recreational activity performed on each day. Hours per week spent in moderate-to-vigorous
intensity aerobic activity were determined using Ainsworth’s Compendium of Physical
Activities[14].
Anthropometrics. Height and weight were measured at baseline and 6 months and BMI was
calculated. Participants were weighed in light indoor clothing, without shoes, rounding up to the
nearest 0.1 kg; height was measured in a standard manner, without shoes, using a stadiometer,
rounding up to the nearest 0.1 cm. All measures were performed and recorded twice in
succession by the same technician and averaged for data entry.
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Exercise Intervention
The exercise intervention group received social and behavioral support and research staff
contact time to encourage them to increase their exercise level to include twice weekly strengthtraining sessions and 150 min of aerobic exercise per week (e.g., three 50-min aerobic exercise
sessions or five 30-min sessions) over 6 months. The trainer and participant(s) met at a local gym
designated by the study weekly during designated times.
Strength Training Sessions: Each strength training session was ~45 minutes. Six common
strength-training exercises were performed using variable resistance machines (for muscles of
the chest, back, shoulders, quadriceps, hamstrings, and gluteals, as well as biceps and triceps).
We used the protocol developed by Katie Schmitz and colleagues. Their protocol was used in the
Physical Activity and Lymphedema (PAL) trial of strength training on lymphedema in breast
cancer survivors[15-16].
Aerobic Exercise Intervention: The participants were also required to do aerobic exercise for a total
of 150 min/week (the current PA recommendation[17]), whether it be at the health club or in their
neighborhood. Participants gradually worked up to exercising 150 min per week within the first
two months.
Recording of Strength and Walking Exercise Sessions: Following each strength and aerobic
exercise session, subjects completed a physical activity log. The logs were submitted weekly to the
Exercise Trainer, who reviewed the log in the presence of the participant. If two days of strength
training and 150 min/wk of aerobic exercise were not performed in the previous week, the trainer and
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participant discussed the barriers experienced by the participant which prevented the participant from
fulfilling the prescribed exercise regimen.
Usual Care
Immediately after randomization, participants in the usual care group were provided
written information that emphasized the importance of a healthy lifestyle. Participants were
encouraged to follow the NCI and ACS physical activity guidelines. Each month, women
randomized to usual care were contacted by a trained health professional to discuss health
education topics relevant to breast cancer survivors. Health education sessions that focused on
issues relevant to women taking AIs, and breast cancer survivors in general, were included.
Statistical Analysis
Participants were grouped according to the intention-to-treat procedure in which all
participants were grouped according to their intervention assignment at randomization regardless
of adherence. A sample size of 39 women was used at the time of this preliminary analysis
because this was the number of participants who had completed 6-months of the intervention as
of March 1, 2012. T-tests and χ2 analyses were used to assess between-group differences at
baseline. The endocrine-related QOL score was calculated by subtracting each individual answer
for each question from 4 and totaling the sum from the 19 questions with a total possible score of
0 to 76, with higher scores indicating better QOL. The total summed scores for the exercise and
usual care groups were then compared using a t-test. A t-test was also used to test for significant
within group differences between baseline and 6 months. Differences in response between the
groups on a per question basis were also examined using t-tests. Changes in endocrine-related
12

QOL by adherence to the intervention were examined in the exercise group only. Changes in the
FACT-B by intervention group were also examined by scoring and summing the FACT-B in a
similar manner to the endocrine subscale where answers to negative questions were subtracted
from 4 and positive questions were scored as the answer on the number scale given. The
individual subscales of the FACT-B (physical (7 items, possible score range 0-28 points), social
(7 items, possible score range 0-28 points), emotional (6 items, possible score 0-24 points),
functional (7 items, possible score range 0-28 points), and breast cancer (9 items, possible score
range 0-36 points) subscales) were scored and examined separately. Aggregate scores for the
FACT-B (which included the physical, social, emotional, functional, and breast cancer
subscales) and FACT-B +ES were calculated as well (possible score range 0-144 and 0-220,
respectively). T-tests were used to assess differences between intervention groups at baseline, 6
months, and changes over the intervention period for each subscale separately as well as the
aggregate scores for the FACT-B and FACT-B + ES. Additionally, regression analysis was used
to build a model to determine if there were any baseline characteristics associated with
endocrine-related QOL at baseline. Statistical analyses were performed using SAS software
(version 9.2; SAS Institute Inc, Cary, NC).

Results
Baseline characteristics
Baseline demographic and physiologic data in the exercise and usual care groups were
similar (Table 2). The average age of study participants was 62.7 years. The majority (87.2%) of
participants were non-Hispanic white. The participants were, on average, overweight at baseline
13

(average BMI 28.8) and averaged 62.9 minutes per week of recreational exercise on the daily
activity log. Average time since breast cancer diagnosis was 2.7 years. The average length of
time participants had been taking an AI was 2.1 years.
Change in physical activity levels and adherence to the exercise intervention
At baseline, the participants in both groups averaged 71.6 minutes per week of exercise
and no strength training over the previous six months as measured by the PAQ. On average,
exercisers increased their weekly activity, as measured by the PAQ, by 195.5 minutes per week
at six months while the usual care group increased their weekly activity by 39.6 minutes per
week (p=0.0008). Exercisers increased their weekly strength training by 58.6 minutes compared
to controls who increased strength training by 7.4 minutes per week (p<.0001).
When examining adherence to the exercise intervention among women randomized to
exercise, as measured by the 7-day Physical Activity Log, on average, exercisers completed 135
minutes per week of moderate-to-vigorous intensity exercise over the 6 month study period, and
47.2% reported participating in at least 150 min/wk of exercise. 57.1% reported participating in
120 min/wk of exercise (80% of the goal). Attendance to the twice-weekly in-person/supervised
exercise sessions was 83.1%, with 81.0% of the exercisers attending at least 70% of the gym
sessions and 61.9% attending at least 80% of the gym sessions (Table 3).
Baseline endocrine-related QOL by treatment group
The average baseline endocrine-related QOL score was 56.2 for all participants in the
study. This score was out of 76 possible points with a higher score being indicative of a higher
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measure of quality of life. The average score did not differ by treatment group (p=0.81). Each
question was broken down individually to detect differences between the treatment groups by
question. There were no statistical differences between the groups by question at baseline (all
p>0.05). The association between baseline characteristics and baseline endocrine-related QOL
was examined. Only age was associated with the measure—as age increased by one year the
endocrine-related QOL score increased by 0.74 points.
Effect of exercise vs. usual care on endocrine-related QOL
Mean 6-month changes from baseline for exercisers for the full QOL endocrine subscale
was +3.3 compared to usual care (+1.8) (Table 4). The difference between the two groups was
not statistically significant (p=0.32). The questions were broken down into four groups by
symptom type: vasomotor (hot flashes, cold sweats, night sweats), neuropsychological
(lightheaded/dizzy, headaches, mood swings, irritableness), gastrointestinal (weight gain,
vomiting, diarrhea, bloating), and gynecological (vaginal discharge, itching, bleeding, dryness,
discomfort during intercourse, loss of interest in sex, breast tenderness)—so as to look for
differences between groups for different types of symptoms. No significant differences were
detected between the two groups. When each item on the endocrine subscale was evaluated
independently, a significant difference between the exercisers and usual care group for favorable
changes in joint pain was observed (p-value = 0.014). A moderately significant effect was also
seen for favorable changes on bloating in exercisers as compared to the usual care group (p-value
= 0.055). See Table 5 for complete results.
Effect of exercise on endocrine-related QOL stratified by potential effect modifiers
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Several variables were examined as potential effect modifiers on the change in endocrinerelated QOL including age, BMI, and time on AI. No effect modification was seen in this
sample.
Effect of exercise on endocrine-related QOL stratified by adherence
Participants were classified as high adherers if they attended more than 80% of gym
sessions or averaged at least 150 minutes of recreational exercise per week throughout the 6month intervention. The effect of adherence on endocrine-related quality of life was not
significant for percent of gym sessions attended, minutes per week of recreational exercise, or a
combination of the two measures. These findings remained even when we defined high adherers
differently, e.g., 70% of gym sessions or the median value.
Effect of exercise on endocrine-related QOL stratified by weight loss
On average, participants in the exercise group lost 1.76 pounds over the 6-month
intervention period compared with 0.40 pounds lost among participants in the control group.
Exercisers who lost weight had higher session attendance than those exercisers who maintained
weight (87.1% vs. 78.6%, p=0.12) but reported similar average minutes per week spent doing
moderate-to-vigorous aerobic exercise (140.5 vs. 158.9, p=0.51). When exercisers were stratified
by weight loss vs. maintaining weight, there was a significant difference in changes in endocrinerelated QOL. Exercisers who lost weight averaged a 5.4 increase in endocrine-related QOL
whereas exercisers who maintained their weight averaged a 1.0 increase (p=0.049) (Table 6).
Effect of exercise vs. usual care on overall QOL measured by FACT-B
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There were no significant differences at baseline between the intervention and usual care
groups for overall FACT-B scores or any of the subscales (physical, social, emotional,
functional, and breast cancer) (Table 3). Mean 6-month changes from baseline for exercisers for
the FACT-B were +10.4 compared to usual care (+3.6). The difference between the two groups
was moderately significant (p=0.097). When each subscale was examined separately there were
significant differences in changes over 6-months for the physical well-being and social/family
well-being subscales. Exercisers increased by 2.5 points on the physical well-being scale and 2.0
points on the social/family well-being scale compared to 0.1 and -0.3, respectively, for the usual
care group (p=0.034, p=0.037, respectively). A moderately significant effect was detected for the
entire FACT-B-ES 6-month changes between the exercisers and usual care group (p=0.081). The
full list of group means and p-values for between group differences for the FACT-B and
subscales can be found in Table 4.

Discussion
In this study, aerobic exercise, such as treadmill walking, and strength training were
associated with increases in endocrine-related quality of life. In particular, the intervention was
associated with significant decreases in joint pain. As joint pain is a significant concern for breast
cancer survivors taking AIs, this finding is of particular importance. Adverse events associated
with taking AIs are the main reason for treatment discontinuation[18]. These results are
encouraging for post-menopausal women who are recommended to take AIs to improve their
prognosis.
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Due to adverse symptoms and treatment, cancer survivors may have difficulty changing
physical activity levels[19]. The breast cancer survivors in this study were all experiencing pain
associated with taking an AI for cancer treatment. This intervention was effective in getting these
breast cancer survivors to increase their exercise levels indicating that even survivors
experiencing moderate to severe adverse treatment-associated symptoms can increase their
exercise levels. Furthermore, this increase in physical activity can alleviate pain associated with
AI use.
Age was significantly associated with increased baseline endocrine-related QOL scores.
This may be due to older women being less bothered by endocrine therapy side effects because
of expected age-related declines. Younger women may feel that they are more limited in their
abilities or have poorer overall health than their peers compared to older women which may
influence the impact of endocrine therapy on quality of life. Other studies have shown that older
breast cancer survivors are less affected by treatment over a variety of measures including
health-related QOL[20-21].
The improvement in endocrine-related QOL observed among the exercise group was also
observed among the usual care group, yet at a lower rate of improvement; thus, the between
group differences in change in endocrine-related QOL was not significant. It is possible that this
amount of time is not enough to measure favorable changes in many endocrine symptoms related
to AI use. However, the intervention described in this study is a 12-month intervention so further
results will allow for a potentially more meaningful effect of exercise on endocrine symptoms.
The small sample size may also have inhibited us from finding a significant difference between
the groups.
18

There was no effect of adherence on endocrine-related QOL scores. This may be because
almost all of the participants attended at least 70% of the gym sessions and exercised
recreationally for more than 110 minutes per week. While there were no incentives for
attendance, the women were likely motivated to attend due to the free gym membership and
personal trainer. With such a small sample size of exercisers it may have been difficult to detect
a difference by adherence to the study goals due to low statistical power. However, the HOPE
study described is set to enroll approximately 90 exercisers total which will potentially allow for
a dose-response relationship with exercise on endocrine-related QOL to be detected. However,
when stratified by weight loss, there was a significant difference in endocrine-related QOL. It
may be that weight loss is a good predictor of true adherence to the study exercise goals.
A moderately significant effect of exercise was detected on the FACT-B +ES and the
FACT-B QOL scales. This suggests that exercise may have an impact on overall QOL in breast
cancer survivors. The FACT-B subscales allow for different aspects of QOL to be examined. A
significant effect of exercise was seen in particular for the physical well-being and social/family
well-being subscales. The participants in our study had normal levels of physical well-being for
women taking AIs at baseline and this value increased over the study period to scores much
closer to published values for women not undergoing endocrine-therapy[3]. It is well established
that exercise is associated with more beneficial physical health outcomes, including better
general and health-related QOL[22]. The participants had high levels of social well-being at
baseline which increased over the study period for the exercise group. The social subscale may
have shown a significant effect of exercise due to the social nature of the exercise-trainer
sessions and the interaction between participants at gym sessions. The participants in our study
19

had high levels of emotional well-being as compared to previous studies of women undergoing
various types of endocrine therapy so an increase in this measure may not have been seen due to
the ceiling effect[3]. Although the participants in our study had relatively low scores on the
breast cancer subscale which increased across the 6 month intervention period, a significant
difference was not seen between the two groups (though the increase for the exercise group was
2-fold higher than the usual care group); however, a significant difference may be seen with a
larger sample size.
One limitation of this study is that we did not screen on FACT-B-ES so there may be
women who already had a high or healthy/normal FACT-B-ES at baseline and therefore no
change was able to be observed. However, we did screen on other AI side effects, (i.e.,
arthralgias, pain/stiffness). Compared to other studies looking at FACT-B and FACT-B-ES QOL
scales for breast cancer survivors currently taking AIs, the women in this study had lower scores
for both measures[3]. The QOL scores for the women in this study were also lower than
published values for breast cancer survivors not undergoing endocrine therapy. The endocrine
subscale for women in our study had an average score of 55.2 (S.D. 8.9) at baseline compared to
published values of 62.4 (S.D. 7.4) for women taking AIs, but not necessarily experiencing side
effects, and 61.1 (S.D. 10.5) for women not taking AIs[3]. Given that this sample does have
some adverse AI side effects, it is reasonable and somewhat expected that they had a lower or
impaired FACT-B-ES as compared to breast cancer survivors undergoing endocrine therapy with
AIs who may or may not be experiencing pain associated with AI use.
This is the first study to examine the effect of exercise specifically on endocrine-related
QOL. Other studies have used various approaches to improving endocrine symptoms in breast
20

cancer survivors including mindfulness-based stress reduction[23], acupuncture[24], physical
therapy, and targeted heat[18]. Pharmacological therapies such as use of non-steroidal antiinflammatory drugs (NSAIDS), cyclooxygenase-2 (COX-2) inhibitors, glucosamine, and
narcotic analgesics have also been studied but may be contraindicated or ineffective[18]. None of
these non-pharmacological or pharmacological therapies have been shown to sufficiently
effective in alleviating symptoms. Therefore, there is a strong need to develop better therapies to
improve endocrine symptoms.
New joint symptoms/pain or vasomotor symptoms, which are common with AI endocrine
therapy, are an indicator of more beneficial treatment outcomes including breast cancer
recurrence[25]. While the reasoning is not fully understood, this provides strong evidence for the
need for beneficial interventions that can improve these symptoms which are worse in women
who may benefit the most from AI treatment. Further research is needed to better understand
why some women experience worse symptoms than others and the role of exercise in alleviating
these adverse symptoms to increase adherence to endocrine therapy.

Conclusions
Given the effectiveness of AIs in improving risk of recurrence and breast cancer death,
and the resulting strong recommendation by clinicians for their patients to take AIs,
understanding how to decrease the severity of AI side effects is necessary. Since side effects
associated with AI use are quite common and this is the main reason for treatment
discontinuation, this innovative non-pharmacologic intervention could benefit a large number of
breast cancer survivors and increase the successful implementation of AIs in breast cancer
21

treatment. In our study, favorable changes in certain endocrine-related quality of life symptoms
were observed. The effect of exercise on these symptoms is promising for breast cancer
survivors whose physicians’ have recommended AIs for treatment.
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Appendix 1
FACT-B
Below is a list of statements that other people with cancer have said are important to their quality
of life. Please indicate the extent to which you have experienced each of the statements during
the past 7 days by circling the appropriate number using the following scale.
0
1
2
3
4
not at all
a little bit
somewhat
quite a bit
very much
During the PAST WEEK:
PHYSICAL WELL - BEING
1. I have a lack of energy.

0

1

2

3

4

2. I have nausea.

0

1

2

3

4

3. Because of my physical condition, I have trouble
meeting the needs of my family.

0

1

2

3

4

4. I have pain.

0

1

2

3

4

5. I am bothered by side effects of treatment.

0

1

2

3

4

6. I feel sick.

0

1

2

3

4

7. I am forced to spend time in bed.

0

1

2

3

4

SOCIAL/FAMILY WELL - BEING
8. I feel close to my friends.

0

1

2

3

4

9. I get emotional support from my family.

0

1

2

3

4

10. I get support from my friends.

0

1

2

3

4

11. My family has accepted my illness.

0

1

2

3

4

12. I am satisfied with family communication about
my illness.

0

1

2

3

4

13. I feel close to my partner (or the person who is
my main support).

0

1

2

3

4

14. I am satisfied with my sex life.

0

1

2

3

4
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During the PAST WEEK:
EMOTIONAL WELL - BEING
15. I feel sad.

0

1

2

3

4

16. I am satisfied with how I am coping with my illness.

0

1

2

3

4

17. I am losing hope in the fight against my illness.

0

1

2

3

4

18. I feel nervous.

0

1

2

3

4

19. I worry about dying.

0

1

2

3

4

20. I worry that my condition will get worse.

0

1

2

3

4

21. I am able to work (include work at home).

0

1

2

3

4

22. My work (include work at home) is fulfilling.

0

1

2

3

4

23. I am able to enjoy life.

0

1

2

3

4

24. I have accepted my illness.

0

1

2

3

4

25. I am sleeping well.

0

1

2

3

4

26. I am enjoying the things I usually do for fun.

0

1

2

3

4

27. I am content with the quality of my life right now.

0

1

2

3

4

FUNCTIONAL WELL - BEING
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During the PAST WEEK:
ADDITIONAL CONCERNS
28. I have been short of breath.

0

1

2

3

4

29. I am self-conscious about the way I dress.

0

1

2

3

4

30. My arms are swollen or tender.

0

1

2

3

4

31. I feel sexually attractive.

0

1

2

3

4

32. I have been bothered by hair loss.

0

1

2

3

4

33. I worry about the risk of cancer in my family.

0

1

2

3

4

34. I worry about the effect of stress on my illness.

0

1

2

3

4

35. I am bothered by a change in weight.

0

1

2

3

4

36. I am able to feel like a woman.

0

1

2

3

4
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Table 1: Endocrine Subscale for the FACT-B
Please indicate how true each statement has been for you during the past 7 days
Endocrine Symptom Subscale
Not at all A little
SomeQuite a
bit
what
bit
I have hot flushes
0
1
2
3
I have cold sweats
0
1
2
3
I have night sweats
0
1
2
3
I have vaginal discharge
0
1
2
3
I have vaginal itching/irritation
0
1
2
3
I have vaginal bleeding or spotting
0
1
2
3
I have vaginal dryness
0
1
2
3
I have pain or discomfort with intercourse
0
1
2
3
I have lost interest in sex
0
1
2
3
I have gained weight
0
1
2
3
I feel lightheaded/dizzy
0
1
2
3
I have been vomiting
0
1
2
3
I have diarrhea
0
1
2
3
I get headaches
0
1
2
3
I feel bloated
0
1
2
3
I have breast sensitivity/tenderness
0
1
2
3
I have mood swings
0
1
2
3
I am irritable
0
1
2
3
I have pain in my joints
0
1
2
3

Very
much
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
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Table 2: Baseline Characteristics of randomized participants in the HOPE study (N=39)
Exercisers
mean (SD)
or %
21
63.0 (7.0)

Usual care
mean (SD)
or %
18
62.4 (6.8)

N
Age (y)
Ethnicity (%)
Non-Hispanic white
81.0
94.4
African-American
14.3
0.0
Hispanic
4.8
5.6
Education (%)
Less than High School graduate
0.0
5.6
High School graduate
9.5
0.0
Some school after high school
38.1
38.9
College graduate +
52.4
55.6
Time since diagnosis (y)
2.6 (1.4)
2.8 (1.2)
Disease stage (%)
Stage I
52.4
50.0
Stage II
28.6
38.9
Stage III
14.3
5.6
Unknown
4.8
5.6
Treatment (%)
None
14.3
11.1
Radiation only
33.3
44.4
Chemotherapy only
4.8
11.1
Radiation and chemotherapy
47.6
33.3
Time on AI (y)
2.0 (1.5)
2.3 (1.2)
Weight (kg)
77.1 (17.3)
73.4 (12.6)
BMI (kg/m2)
29.9 (7.5)
27.9 (5.7)
1
Physical Activity Questionnaire
76.4 (125.6)
65.9 (73.2)
(min/wk recreational exercise)
Daily Activity log2
52.1 (72.3)
75.4 (105.7)
(min/wk recreational exercise)
No statistically significant differences between exercise and usual care groups at baseline.
1
Mean min/week of moderate- to vigorous-intensity sports/recreational physical activity as
determined from the baseline physical activity questionnaire that assessed activity levels for 6
months prior to study enrollment
2
Mean min/week of moderate- to vigorous-intensity sports/recreational physical activity at
baseline as determined from the 7-dy Daily Activity Log
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Table 3: Adherence from baseline to 6-months in the HOPE study (N=39)
Baseline to 6 Months
Min/week
Mean (SD)
% of goal
% of subjects adhering to
≥ 150 min/week (100%)
≥ 120 min/week (80%)
≥ 90 min/week (60%)
≥ 60 min/week (40%)
≥ 30 min/week (20%)

135 (71.9)
90%
43%
57%
76%
91%
100%
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Table 4: Change in Fact-B and subscales from baseline to 6-months by randomization group
Exercisers
mean (SD)

Usual care
mean (SD)

p-value

Endocrine Subscale
Baseline
6 months
Change from baseline to 6 months

56.5 (9.0)
59.9 (9.4)
3.3 (5.2)

55.8 (10.1)
57.7 (9.1)
1.8 (3.5)

0.81
0.46
0.32

FACT-B
Baseline
6 months
Change from baseline to 6 months

99.5 (19.6)
109.9 (14.9)
10.4 (14.2)

101.6 (10.9)
105.1 (15.1)
3.6 (10.2)

0.68
0.33
0.097

Physical Well-Being
Baseline
6 months
Change from baseline to 6 months

21.1 (4.3)
23.6 (2.7)
2.5 (3.8)

22.6 (2.9)
22.7 (3.6)
0.1 (2.7)

0.25
0.34
0.034

Social/Family Well-Being
Baseline
6 months
Change from baseline to 6 months

21.6 (5.7)
23.7 (4.7)
2.0 (3.4)

21.1 (5.3)
20.7 (5.3)
-0.3 (3.5)

0.76
0.077
0.037

Emotional Well-Being
Baseline
6 months
Change from baseline to 6 months

18.6 (4.2)
19.9 (4.2)
1.2 (2.6)

18.9 (2.2)
20.4 (2.6)
1.6 (2.9)

0.80
0.60
0.72

Functional Well-Being
Baseline
6 months
Change from baseline to 6 months

19.8 (5.4)
22.0 (4.4)
2.2 (5.7)

20.3 (3.4)
21.4 (4.7)
1.1 (4.0)

0.73
0.66
0.47

Breast Cancer Subscale
Baseline
6 months
Change from baseline to 6 months

18.3 (4.9)
20.7 (3.6)
2.4 (3.5)

18.7 (3.7)
19.9 (4.0)
1.2 (2.2)

0.77
0.52
0.21

FACT-B + ES
Baseline
6 months
Change from baseline to 6 months

156.0 (27.0)
169.8 (21.7)
13.7 (16.5)

157.4 (17.1)
162.8 (18.3)
5.4 (11.6)

0.86
0.29
0.081
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Table 5: Changes in ES for individual questions by randomization group
Exercisers
Mean (SD)

Usual Care
Mean (SD)

Vasomotor
Hot flashes
Cold sweats
Night sweats

0.2500
0.2381
0.0476

0.3889
0.2222
0.3889

p-value
0.58
0.72
0.97
0.30

Neuropsycological
Lightheaded/dizziness
Headaches
Mood swings
Irritableness

-0.0476
0.0476
0.2857
0.3810

0.2222
0.0556
0.5000
0.3333

0.47
0.31
0.97
0.47
0.89

Gastrointestinal
Weight gain
Vomiting
Diarrhea
Bloating

0.5714
0
-0.0952
0.5238

0.5556
0
0.0556
0

0.46
0.97
n/a
0.39
0.055

Gynecological
Vaginal discharge
Vaginal itching/irritation
Vaginal bleeding
Vaginal dryness
Discomfort during intercourse
Loss of interest in sex
Breast sensitivity/tenderness

-0.1429
-0.0476
0
0.2857
-0.2000
-0.1905
0.1429

0
-0.2222
0
-.4444
-0.0588
0
-0.3333

0.27
0.43
0.52
n/a
0.024
0.71
0.73
0.17

Other
Joint pain

1.0476

0.2778

0.014
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